TRV734

About Trevena

Trevena is a clinical-stage biopharmaceutical company with a pipeline of novel CNS therapies stemming from Nobel Prize-winning research on G protein-coupled receptor (GPCR) signaling. Its sole approved asset, OLINVYK® (oliceridine), is an IV analgesic for acute pain, but commercial traction has been limited. The company faces significant financial and operational challenges, including a recent delisting from Nasdaq and a market valuation of zero, while advancing early-stage candidates for neuropathic pain, migraine, and opioid use disorder. Its survival hinges on securing additional capital and demonstrating clinical proof-of-concept for its pipeline assets.

Therapeutic Areas